F40-4 ameliorates hyperuricemia by modulating the gut microbiota and alleviating inflammation in mice.

Hyperuricemia (HUA) is a systemic disease characterized by a disorder of purine metabolism and an abnormal increase in the serum level of uric acid (UA). Probiotics can exert potential therapeutic benefits against some metabolic diseases by regulating the intestinal microbiota. F40-4 with UA-lowering activity of 87.40% was screened using purine as the target . The UA-lowering activity of F40-4 was further explored in a mouse model of HUA . F40-4 could downregulate serum levels of UA, blood urea nitrogen, creatinine, and xanthine oxidase by 40.84%, 11.61%, 57.66%, and 41.79%, respectively. F40-4 restored organ damage, and adjusted enzyme activity and transporter expression to promote the metabolic level of UA. In addition, F40-4 could reshape the gut microbiota and suppress inflammation to ameliorate HUA. An increment in intestinal UA excretion was documented. These findings suggest that F40-4 might serve as a potential probiotic for the prevention and treatment of HUA.